Objective To evaluate response to low dose oxybutynin in children with nocturnal enuresis.
Materials and Methods Forty one out of 111 neurologically normal enuretic children who referred nephrology clinic in a 3- year period (2007–2009)received low dose oxybutynin (2.5–10 mg/day depending on the age) to define response to the drug in one and 3- month periods .No response, partially and full responses were defined as decreased in bed wetting in the rate of 0–49%, 50–89% and ≥90% respectively.
Results In first month of treatment, full, partial and no responses were reported in 3 (7.3%), 14 (34.1%) and 24 (58.6%) patients respectively. In non-responder patients 6 (25%) and 5) 20.8 % (patients had full and partial responses in 3-month period, whereas 13 (54.2%) had no response. Side effects of the drug were reported in 5 (12.2%) patients .Children with non-mono symptomatic nocturnal enuresis presented a better response to the drug than those with mono symptomatic nocturnal enuresis (75% versus 25%). There was no significant differences between age, gender, family history of enuresis and presence of absence of daytime urinary or bowel symptoms in responder and non-responder groups (p>0.05 for all).
Conclusion In the present study which is a clinical report study with no control group, there was 68.3% treatment benefit and 12 % risk (side effects of the drug) with low dose oxybutynin, so it may have a role in treating nocturnal enuresis especially patients with NMNE who experience adverse effects of the drug with standard treatment.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.